CUE Cue Biopharma Inc

Cue Biopharma to Present Corporate Update at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Cue Biopharma to Present Corporate Update at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

BOSTON, Feb. 06, 2024 (GLOBE NEWSWIRE) --  (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that it will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference being held virtually from February 13-14, 2024.

During the presentation, Cue Biopharma’s chief executive officer, Dan Passeri, will provide a corporate update highlighting the latest developments from its lead clinical programs, CUE-101 and CUE-102, its lead preclinical autoimmune program partnered with Ono Pharmaceutical, as well as market opportunities, competitive positioning and key forecasted value-driving 2024 milestones.



Presentation Details

Oppenheimer 34th Annual Healthcare Life Sciences Conference

Date and Time: Tuesday, February 13, 9:20 a.m. EST

Webcast Link:

Presenter: Daniel Passeri, M.Sc., J.D., chief executive officer, Cue Biopharma

A live and archived webcast of the presentation will be available on the Events page in the Investors and Media section of the Company’s website at . The webcast will be archived for 30 days.

About Cue Biopharma

Cue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. The company’s proprietary platform, Immuno-STAT™ (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body’s intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation.

Headquartered in Boston, Massachusetts, we are led by an experienced management team and independent Board of Directors with deep expertise in immunology and immuno-oncology as well as the design and clinical development of protein biologics.

For more information please visit  and follow us on  and .

Investor Contact

Marie Campinell 

Senior Director, Corporate Communications

Cue Biopharma, Inc.

Media Contact

Jonathan Pappas

LifeSci Communications



EN
06/02/2024

Underlying

CUECue Biopharma Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cue Biopharma Inc

 PRESS RELEASE
Free
CUE Cue Biopharma I...

Cue Biopharma Reports Second Quarter 2025 Financial Results and Recent...

Cue Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights Received FDA feedback on Pre-IND Briefing Document reinforcing Company’s intention to advance investigational new drug (IND) submission for CUE-401 to address unmet need in the treatment of autoimmune disease. Announced strategic research collaboration and license agreement with Boehringer Ingelheim to develop and commercialize CUE-501, a differentiated B cell depletion therapy for autoimmune and inflammatory diseases. Upfront payment of $12 million and ~$345 million in potential milesto...

2h / 4m 1 EN
 PRESS RELEASE
Free
CUE Cue Biopharma I...

Cue Biopharma Reports New Complete Response and Confirmed 50% Overall ...

Cue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase 1 Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV+ Head and Neck Cancer Additional complete response (CR) observed in patient with multiple tumorsConfirmed overall response rate (ORR) of 50% in patients with combined positive score (CPS) ≥1, including 50% ORR in patients with low CPS (1-19)12-month overall survival of 88% and median overall survival (mOS) of 32 months BOSTON, July 16, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: CUE), a clinical-stage biopharmaceutical company de...

July 16, 2025 1 EN
 PRESS RELEASE
Free
CUE Cue Biopharma I...

Cue Biopharma Provides Update on Most Advanced Clinical Stage Asset, C...

Cue Biopharma Provides Update on Most Advanced Clinical Stage Asset, CUE-101, Presented by Dr. Dimitrios Colevas at the DAVA 4th Hawaii Global Summit on Thoracic Malignancies ORR of 50% in treatment-naïve patients with HPV+ R/M HNSCC12-month landmark survival of 88% and mOS of 32 months BOSTON, July 01, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease and cancer, today provided an update on its most advanc...

July 1, 2025 1 EN
 PRESS RELEASE
Free
CUE Cue Biopharma I...

Cue Biopharma Receives FDA Feedback on Pre-IND Briefing Document Reinf...

Cue Biopharma Receives FDA Feedback on Pre-IND Briefing Document Reinforcing Company’s Intention to Advance IND Submission for CUE-401 to Address Unmet Need in the Treatment of Autoimmune Disease CUE-401, a first-in-class bispecific molecule designed to induce and expand Tregs in vivo through the co-activity of transforming TGF-β and a modified variant of IL-2 BOSTON, June 24, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment o...

June 24, 2025 1 EN
 PRESS RELEASE
Free
CUE Cue Biopharma I...

Cue Biopharma Reports First Quarter 2025 Financial Results and Recent ...

Cue Biopharma Reports First Quarter 2025 Financial Results and Recent Business Highlights Announced Boehringer Ingelheim strategic collaboration and license agreement for CUE-501, including an upfront payment of $12 million and ~$345 million in potential milestone payments Raised gross proceeds of ~$20 million in follow-on capital raise Successfully regained worldwide rights for lead autoimmune program, CUE-401, with potential to become a new standard of care for autoimmune and inflammatory diseases Virtual Event planned for May 15, 2025 at 11 AM ET, featuring two prominent Key Opinion L...

May 12, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch